Zacks Investment Research on MSN

GEHC moves manganese-based MRI contrast agent into phase 2/3 trial

GE HealthCare Technologies Inc. GEHC recently announced that the first patient has been dosed in its Phase 2/3 LUMINA ...

GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation ...

GE HealthCare announces first patient dosed in Phase 2/3 LUMINA trial for manganese-based MRI contrast agent under FDA Fast Track designation ...
Healio

Virtual chest X-ray with phase-contrast imaging detects small-airway obstruction

Please provide your email address to receive an email when new articles are posted on . With this detection ability, asthma and COPD could be more clearly displayed to clinicians during screening, ...
EurekAlert!

Aberration-free quantitative phase imaging

Figure 1： The flowchart of ACDPC iterative reconstruction joint optimization algorithm. (a) ACDPC imaging system based on half-annular illumination. (b) Three annular illumination patterns and their ...
EurekAlert!

Innovative method for 3D quantitative phase imaging

Light waves, as they propagate through a medium, experience a temporal delay. This delay can unveil crucial information about the underlying structural and compositional characteristics. Quantitative ...

(CNW) Bracco Receives Health Canada Approval for VUEWAY(R) injection (gadopiclenol), Advancing Lower-Dose MRI Contrast Imaging

MONTREAL, April 17, 2026 /CNW/ -- Bracco Imaging, a global leader in diagnostic imaging, today announced that Health Canada approved VUEWAY (R) injection (gadopiclenol), a macrocyclic gadolinium-based ...